Table 1.

FDA-approved PARP1 inhibitors.

PARP1 inhibitors	Year of FDA Approval	Disease Indication
Olaparib (AZD-22S1)	2014	Ovarian cancer (BRCA mutated)
	2016	ATM-mutated, castration-resistant prostate cancer (BRCA mutated)
	2018	HER2-negative, advanced breast cancer (germline BRCA)
Rucaparib (AG-014699)	2016	Ovarian cancer (BRCA mutated)
Niraparib (MK-4827)	2017	Platinum-sensitive, relapsed ovarian cancer in post-chemotherapy maintenance
Talazoparib (BMN-673)	2018	Germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer

Olaparib has never been approved for prostate cancer.